391 results about "Vaccine adjuvant" patented technology

The invention discloses a GPC3 derived antigen peptide vaccine, an mRNA vaccine, a saRNA vaccine and a preparation method and application thereof. The amino acid sequence of the antigen peptide vaccine is one or any combination of more of amino acid sequences shown as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6. According to the invention, an efficient pGPC3 model antigen peptide is screened on the basis of GPC protein, and pGPC3 mRNA and pGPC3 saRNA are designed according to a pGPC3 sequence example. The pGPC3saRNA (at) Lipi vaccine is prepared through a liposome technology, and due to the fact that limiting conditions such as nonapeptide and high-affinity binding with H-2I type molecules (H-2Kb) are adopted during pGPC3 polypeptide antigen screening, APC cells are facilitated to present antigens through an MHCI restrictive pathway, CD8 + T cells are activated, and GPC3 specific CTL is triggered to efficiently kill liver cancer cells. Finally, the pGPC3saRNA (at) Lipi vaccine can completely inhibit the growth of the liver cancer, the inhibition rate reaches 99.8%, and the liver cancer of 4 / 8 mice completely fades down. In addition, the method can be used for vaccine adjuvant and carrier research on a liver cancer subcutaneous transplantation tumor model.

The invention discloses an adjuvant and application thereof in vaccine preparation. The amino acid sequence of the adjuvant is shown as SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 23, 27, 31, 35 or 39. The immune protection effect of the nanoparticle vaccine can be improved by activating TLR2, and good vaccine adjuvant activity is shown in a common immunogen SD or new coronavirus RBD immunogen model. Furthermore, an assembly construction method of the self-adjuvant-nanoparticle vaccine is optimized, and the prepared self-adjuvant-nanoparticle vaccine has a remarkable effect of inducing the generation of an antibody in an animal body. The novel adjuvant provided by the invention can be widely applied to vaccine research and development, and meanwhile, the assembled nanoparticle self-adjuvant vaccine can also become a novel vaccine.

Disclosed are immunologically active saponin fraction composition, its method of manufacture and use in vaccine adjuvants, and in adjuvanted vaccines. Methods of preparation, vaccine and treatment kits comprising the adjuvants, and uses of vaccines and vaccine kits comprising the adjuvants are also disclosed.

The present invention provides a composition comprising a universal influenza vaccine antigen and a vaccine adjuvant.

The invention relates to the technical field of vaccine adjuvants, and particularly discloses a preparation method of a nanoscale aluminum hydroxide adjuvant based on organic metal alkoxide hydrolysis. Aluminum isopropoxide is used as a precursor, and a hydrolysis interface is directionally regulated and controlled through a compound surfactant; a staged hydrolysis process is adopted, and a kinetic equation is met; and the surface is modified by a KH-550 coupling agent. According to the preparation method disclosed by the invention, boehmite phase crystallization, nanoscale uniformity and high antigen adsorption stability are synchronously realized at low temperature through alcoholate hydrolysis bond energy reconstruction, surface activity compounding interface regulation and control and staged kinetic control, and the bottlenecks of high temperature, high energy consumption and non-uniform particle size of a traditional process are overturned; and a novel industrial scheme with low consumption and high efficiency is provided for vaccine adjuvants.

The present invention discloses a vaccine adjuvant, a vaccine composition, and a preparation method and application thereof, relating to the field of veterinary technology. The present invention uses safe, stable, and efficient lipophilic and hydrophilic surfactants, which can reduce the body's side effects and accumulation in the body, and has the technical advantage of high safety. The invention helps to improve the quality of veterinary vaccines and reduce the production costs of veterinary vaccine manufacturers. After the vaccine adjuvant is prepared into a vaccine composition, it can effectively enhance the immunogenicity of the vaccine, improve the vaccine's immune effect, and provide long-term and stable immune protection.

The invention discloses a Toll-like receptor stimulant-based vaccine adjuvant lipid compound and application thereof, and particularly discloses a compound as shown in a formula (I), a stereoisomer thereof, an N-oxygen compound thereof, a solvate thereof or a pharmaceutically acceptable salt thereof. The mRNA-TLP composition prepared from the adjuvant lipid compound provided by the invention has significantly improved targeting to mouse spleen antigen presenting cells, and can significantly inhibit tumor growth. # imgabs0 #

An aluminum-manganese composite nanocrystal, and a preparation method therefor and the use thereof. The method for preparing the aluminum-manganese composite nanocrystal comprises: step 1, mixing an aluminum salt solution, a manganese salt solution and an anionic adjuvant solution to obtain a mixture, and adjusting the pH value of the mixture to 5.5-8.5; and step 2, heating the mixture for a reaction, and washing the obtained solid reactant to obtain the aluminum-manganese composite nanocrystal. According to the aluminum-manganese composite nanocrystal prepared using the preparation method and the use thereof in the preparation of a vaccine adjuvant, a pharmaceutical composition, a drug delivery carrier or an immunogenic composition, the technical problem that an existing aluminum adjuvant cannot activate humoral immunity and cell immunity at the same time can be effectively solved.

The invention belongs to the technical field of biological medicine, and particularly discloses a composite vaccine adjuvant as well as a preparation method and application thereof. The composite vaccine adjuvant provided by the invention is an oil-in-water emulsion, and simultaneously contains squalene, polysorbate 80, sorbitan trioleate, polyinosinic acid (Poly I: C) and CpG oligodeoxynucleotide (CpG-ODN). The sequence-optimized CpG-ODN and Poly I: C are used in a specific emulsion system in a combined mode, a remarkable synergistic immune enhancement effect can be generated, the induced humoral immunity and cellular immunity response level is remarkably higher than the sum of the effects when all the components are independently used, and the composite adjuvant is good in stability, high in immunostimulatory activity and suitable for clinical application. The immune effect can be remarkably improved by combined application with various vaccine antigens. The invention also provides a preparation method and application of the composite vaccine adjuvant.

The present invention discloses an enhanced tumor vaccine adjuvant, and specifically relates to the field of vaccine adjuvants, the adjuvant comprising granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-9 (IL-9), gamma interferon (IFN-γ) and at least one additional immunomodulatory factor, wherein the immunomodulatory factor is selected from tumor-specific antigen WT1, CD40 ligand (CD40L), Toll-like receptor agonist or a combination thereof. The tumor vaccine adjuvant of the present invention can enhance the body's immune response to the tumor vaccine and improve the prevention and treatment effect of the tumor vaccine on tumors.

The invention provides an inactivated bacterial preparation as well as a preparation method and application thereof. According to the method, the manganese-containing oxidizing agent and bacterial pathogens are incubated, and the purpose of inactivating bacteria is achieved within a short time by utilizing the strong oxidizing property of the manganese-containing oxidizing agent; and slowly dripping a polyphenol monomeric compound solution into the system, self-polymerizing on the surface of the bacteria under the action of the manganese-containing oxidizing agent, reducing the manganese-containing oxidizing agent to form a manganese adjuvant, attaching the manganese adjuvant to the surface of the bacteria, and simultaneously loading the manganese adjuvant on the surface of the bacteria. The method is suitable for various bacteria and polyphenol monomers. The prepared inactivated bacterial preparation can effectively induce humoral immunity and cellular immunity response of antigen specificity and effectively protect bacterial infection, and has wide application prospects in antibacterial vaccines and vaccine adjuvants.

The present invention relates to CpG oligodeoxyribonucleotides with improved body immunity, combinations thereof with additional adjuvants, and uses of the CpG adjuvants or combinations thereof in various vaccine compositions. The CpG independently serves as an adjuvant or is combined with an existing marketed adjuvant for use, and the CpG has the very remarkable advantages that the immune effect is advanced, the immune effect is improved, the lasting period of the immune protection effect is longer, the potential anaphylactic reaction is lower and the like, is superior to a commercially available vaccine adjuvant or an adjuvant system, and is a very excellent effective component of the vaccine adjuvant or the vaccine adjuvant system.

The invention provides an influenza vaccine adjuvant based on lentinan as well as a preparation method and application thereof. The active ingredient of the vaccine adjuvant is lentinan, the lentinan is extracted from fresh lentinus edodes through a water extraction and alcohol precipitation method, no additional chemical modification is needed, the vaccine adjuvant can be used for preparing the influenza virus vaccine, and the influenza virus vaccine at least contains one of three inactivated influenza virus antigens, namely H1N1 A, H3N2 A and Victoria B. The invention also provides a vaccine preparation and a preparation method thereof, the vaccine preparation comprises the vaccine adjuvant and an influenza virus vaccine, the content of lentinan in the vaccine preparation is 4 mg / mL, and the vaccine preparation has an immunological enhancement effect.

Non-liposome, non-micelle particles formed of a lipid, an additional adjuvant such as a TLR4 agonist, a sterol, and a saponin are provided. The particles are porous, cage-like nanoparticles, also referred to as nanocages, and are typically between about 30 nm and about 60 nm. In some embodiments, the nanocages include or are administered in combination with an antigen. The particles can increase immune responses and are particularly useful as adjuvants in vaccine applications and related methods of treatment. Preferred lipids, additional adjuvants including TLR4 agonists, sterols, and saponins, methods of making the nanocages, and method of using them are also provided.

The invention relates to a universal hydrogel vaccine based on tumor neoantigen peptide as well as a preparation method and application of the universal hydrogel vaccine. The hydrogel vaccine comprises tumor neoantigen peptide hydrogel and an adjuvant loaded on the tumor neoantigen peptide hydrogel, the tumor neoantigen peptide-peptidyl assembly sequence conjugate is assembled in a solvent to form a nanofiber solution, and the nanofiber solution is triggered to form hydrogel under physiological conditions; the conjugate is obtained by coupling a tumor neoantigen peptide and a peptidyl assembly sequence through a covalent bond; the adjuvant is at least any one of a cell factor, an STING agonist, a Toll-like receptor agonist and an immune cell. The vaccine disclosed by the invention has universality, aiming at different tumor neoantigen peptides, self-assembly of a conjugate in a solvent is realized by regulating and controlling the quantity of valine or phenylalanine in a peptidyl assembly sequence to form a nanofiber solution, and the vaccine adjuvant is loaded through physical action to obtain a nanofiber solution containing the vaccine adjuvant; therefore, personalized cancer immunotherapy is realized.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to tubeimoside B liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: dissolving phospholipid, cholesterol and PEGylated phospholipid in an organic solvent to form a mixed solution, and then evaporating the mixed solution to form a film; and hydrating the film by using an aqueous solution of tubeimoside B to finally prepare the tubeimoside B liposome. Compared with free tubeimoside B, the lipidosome has the advantages that the hemolysis percentage is obviously reduced, and antigen-specific humoral immune response and / or cellular immune response can be effectively enhanced when the lipidosome is used as a vaccine adjuvant. In an H1N1 influenza mouse model, the lipidosome combined antigen shows an excellent protection effect, which is shown in that the mouse weight fluctuation is relatively small and the lung virus load is remarkably reduced. The invention provides important theoretical basis and practical examples for developing low-toxicity and high-efficiency plant-derived vaccine adjuvants, and has a wide application prospect.

The invention discloses an ultralow-viscosity water-in-oil vaccine adjuvant and a preparation method thereof, and the ultralow-viscosity water-in-oil vaccine adjuvant comprises the following components in percentage by weight: 73%-75% of oil for injection, 20%-23% of a compound emulsifier, 2%-7% of a stabilizer, 0.5%-1.5% of a chiral immunomodulator and 1%-2% of a temperature-responsive material, the preparation method comprises the following steps: heating oil for injection as an oil phase; adding the compound emulsifier, the stabilizer, the chiral immunomodulator and the temperature response type material into the oil phase, stirring until the materials are completely dissolved to form a uniform oil phase mixture, slowly adding the water phase into the oil phase mixture, performing high-speed shearing to form primary emulsion, homogenizing the primary emulsion, and performing freeze drying to obtain the chiral immunomodulator. And carrying out emulsion refining by adopting a micro-fluidic technology to obtain the ultralow-viscosity water-in-oil type vaccine adjuvant. The ultra-low viscosity and injection comfort are achieved, precise immunization is achieved for different pathogens, multiple immune pathways are activated at the same time, a wide and lasting protection effect is generated by training an immune mechanism, and the ultra-low viscosity and injection comfort have the intelligent drug release characteristic, excellent stability and broad-spectrum applicability.

Provided are a method for enhancing the immune response of a mammal and a composition comprising liposomes, a TLR4 agonist and a TLR7 agonist.

The invention belongs to the technical field of vaccine adjuvants, and particularly relates to a water-in-oil-in-water adjuvant, a veterinary vaccine and a preparation method thereof.The water-in-oil-in-water adjuvant is prepared from, by weight, 0.5%-7.5% of a hydrophilic composite surfactant, 0.6%-9.8% of an oleophylic composite surfactant, 70%-85% of mineral oil and the balance water; and the mineral oil also comprises the following components in concentration: a reinforcing agent of 0.45-0.9 g / ml and a stabilizing agent of 2-6.9 g / L, wherein the water-in-oil-in-water adjuvant forms a gelatinous structure under the regulation of the stabilizer and is a non-Newtonian fluid of which the viscosity is not higher than 25cp; the adjuvant shows the non-flowing fluid characteristic through the stabilizer, the rheological property of the produced vaccine is enhanced, the stability of the vaccine is improved, on the premise that the hydrophilic surfactant and the oleophylic surfactant are balanced, the natural polymer enhancer is added, and on the premise that the adjuvant viscosity is reduced and granuloma side reaction is not prone to being generated, the stability of the vaccine is improved. Short-term immunity and long-term immunity can be induced at the same time, and the application of the water-in-oil-in-water adjuvant in the field of veterinary vaccines is expanded.

The invention belongs to the technical field of biological medicines, and provides a lipidosome nano vaccine taking glycyrrhiza polysaccharide as an adjuvant, which comprises a lipidosome shell consisting of phospholipid and cholesterol, and glycyrrhiza polysaccharide and mode antigen OVA257-264 entrapped in a lipidosome core. The invention also provides a preparation method of the liposome nano vaccine taking glycyrrhiza polysaccharide as the adjuvant. The invention also provides an application of the liposome nano vaccine in preparation of antitumor drugs. The lipidosome nano vaccine taking glycyrrhiza polysaccharide as the adjuvant can target lymph nodes, induce an organism to generate cellular immune response and form immune memory, so that the immunotherapy effect on tumors is remarkably enhanced. As a vaccine adjuvant, glycyrrhiza polysaccharide not only has the advantages of being good in biocompatibility, safe and non-toxic, but also can effectively make up for the limitation that a current tumor vaccine adjuvant is low in efficiency, high in toxicity and insufficient in Th1 response.

The invention discloses a composite adjuvant, and belongs to the field of vaccine adjuvants. The main active components of the composite adjuvant are squalene, polysorbate 80 and monophosphoryl ester A, the composite adjuvant is in an oil-in-water emulsion form, nano-scale emulsion droplet particles are uniformly distributed in a water phase, and the system is stable. The invention also discloses a preparation method of the composite adjuvant based on a stirring method. The composite adjuvant comprehensively utilizes the dual characteristics of the oil-in-water emulsion and the immunopotentiator, and can induce a higher level of immunoreaction when being combined with the antigen, so that the composite adjuvant can be used for preparing vaccines and improving the effectiveness of the vaccines.

A vaccine adjuvant, and a preparation method therefor and a use thereof. The vaccine adjuvant is a MA105 immunologic adjuvant, and comprises (1) QS-21:50 μg / ml to 300 μg / ml; (2) Poly I:C: 400 μg / mL to 3000 μg / mL; and (3) lipid molecules constituting a vector, the vector being a mixture of a cationic liposome and a neutral liposome.

The invention discloses an oil-in-water vaccine adjuvant, an emulsion as well as a preparation method and application of the oil-in-water vaccine adjuvant, and relates to the technical field of vaccine adjuvant preparation. The adjuvant obtained by the invention is still not layered after being subjected to high-temperature and high-pressure moist heat sterilization. The contamination risk when the adjuvant is uniformly mixed after being subjected to high-temperature and high-pressure damp-heat degerming and layering is reduced, and vaccine manufacturers can conveniently carry out next-step production. The antigen and the adjuvant are mixed, and the prepared vaccine has higher immune efficacy than similar oil-in-water adjuvant vaccines. The oil-in-water adjuvant provided by the invention has good vaccine production and application prospects. When a vaccine composition is prepared on the basis of the oil-in-water vaccine adjuvant, high kinetic energy, high shearing, high-speed stirring emulsification and high-pressure homogeneous emulsification are not needed either, the emulsification process is greatly simplified, emulsification can be successful through low kinetic energy stirring, and vaccine production and use are more convenient and efficient.

The invention relates to the technical field of biological medicine, in particular to a vaccine adjuvant containing saponin and a preparation method of the vaccine adjuvant. The vaccine adjuvant containing saponin is prepared from the following raw materials in percentage by mass: 0.05 to 0.2 percent of saponin components, 0.5 to 2.0 percent of phospholipid, 3 to 7 percent of oil phase, 0.5 to 2.5 percent of surfactant, 0.05 to 0.2 percent of antioxidant, 2.5 to 4.0 percent of trehalose, 0.1 to 0.5 percent of novel synergistic polymer and the balance of water for injection, according to the preparation method disclosed by the invention, an innovative preparation process of firstly preparing blank nanoemulsion and then loading saponin is adopted, and a stable protective layer is formed on the interface of the nanoemulsion, so that hemolytic groups of the saponin are effectively shielded, the toxic and side effects of the saponin are remarkably reduced, and the chemical stability of the saponin is protected. The adjuvant disclosed by the invention is good in stability, high in safety and strong in immune effect, and has a good clinical application prospect.

The invention relates to the technical field of veterinary biological products. The invention provides a poultry epidemic disease inactivated vaccine adjuvant as well as a preparation method and application thereof. The adjuvant is prepared from the following raw materials in dosage ratio: 70 to 80mL of white oil, 0.5 to 1.5 mL of Tween-80, 1 to 2g of chitosan, 0.5 to 1.5 g of astragalus polysaccharide and 0.5 to 1.5 g of vitamin E. According to the invention, multiple raw materials are utilized, and a triple synergistic mechanism of long-acting slow release, efficient activation and safety protection is formed through emulsion stabilization and targeted delivery at a physical level, multi-channel activation (including natural immunity, adaptive immunity, humoral immunity and mucosal immunity) at an immune level and synergistic oxidation resistance and inflammatory reaction regulation at a safety level; the immune response efficiency, the antibody duration and the safety of the vaccine can be remarkably improved, and the vaccine is particularly suitable for the special immune physiological characteristics of poultry.

The invention discloses a self-emulsifying adjuvant of a vaccine and a preparation method of the self-emulsifying adjuvant, and relates to the technical field of vaccine adjuvants. The adjuvant comprises an oil phase, an emulsifier and a freeze-drying protective agent, the oil phase comprises squalene and tocopherol, the emulsifier comprises polysorbate and a polyoxyethylene-polyoxypropylene block copolymer, and the freeze-drying protective agent comprises sugar and sugar alcohol. The preparation method comprises the following steps: emulsifying an oil phase and a water phase to form a nano-emulsion, and then freeze-drying to obtain freeze-dried powder. The adjuvant has the advantages of small particle size, uniform distribution, high stability, rapid reconstruction and the like, and can effectively maintain active components and improve the immune effect of vaccines.

The invention discloses neutral homogeneous lycium barbarum polysaccharide as well as a preparation method and application thereof. Through systematic structure characterization, it is clarified for the first time that the polysaccharide NLBPE1 is atypical arabinogalactan with 1, 5-alpha-L-arabinose as a bridging unit, and the polysaccharide NLBPE1 has a uniform molecular weight and a definite branched chain topological structure. The NLBPE1 serving as an adjuvant and an antigen are jointly entrapped in various delivery systems (such as PLGA nanoparticles, lipidosome, hydrogel and the like) to form the vaccine composition, so that the immunogenicity of the vaccine can be remarkably improved, and the antigen-specific T cell response can be enhanced. The invention provides an application scheme of the polysaccharide as a vaccine adjuvant in tumor immunotherapy and tumor prevention, and particularly shows a remarkable synergistic anticancer effect when the polysaccharide is combined with an immune checkpoint inhibitor for use. The polysaccharide has a clear structure, good biocompatibility and remarkable immunological enhancement activity, and has a wide application prospect of tumor vaccine adjuvants.

The present invention pertains to the field of pharmaceutical technology. Specifically, the present invention relates to a zinc risedronate micro / nano adjuvant with sustained-release function formed by mineralization of zinc ions and risedronic acid as main components and its use as a vaccine adjuvant. The present invention also relates to a method for preparing zinc risedronate micro / nano adjuvant. The present invention also relates to a chemical composition, vaccine adjuvant and vaccine composition comprising zinc risedronate micro / nano adjuvant. The present invention also relates to a use of zinc risedronate micro / nano adjuvant as a vaccine adjuvant.

The invention discloses a novel immunologic adjuvant, a composition containing the immunologic adjuvant and a pharmaceutical composition. The immunologic adjuvant is picrasidine S. The immunologic adjuvant composition comprises picrasidine S and optionally one or more other types of immunologic adjuvants, such as an aluminum adjuvant. The pharmaceutical composition comprises an antigen and the immunologic adjuvant composition. Experiments prove that the picrasidine S can effectively stimulate dendritic cells to generate cell factors IFN-beta and IL-6, and has PS dose dependence; picrasidine S plays an important role in enhancing specific humoral immune response of different types of antigens, and has a stronger effect than an aluminum adjuvant; the picrasidine S immunity can enhance the anti-tumor immune response in different tumor models. According to the invention, a new candidate drug is provided for research and development of a new generation of vaccine adjuvants, and meanwhile, the medical application of the picrasidine S is also widened.

The invention relates to an MPL composite adjuvant and a preparation method thereof, and belongs to the technical field of vaccine adjuvants. The composite adjuvant comprises neutral phospholipid, anionic phospholipid, cholesterol, monophosphoryl lipid A, QS-21 and surface modified lipid. The preparation method comprises the following steps: dissolving a lipid component in an organic solvent to form a mixed solution, evaporating the solvent to form a lipid film, adding a buffer solution, hydrating to form a liposome suspension, performing ultrasonic treatment to obtain small single-layer liposome, and mixing the small single-layer liposome with a QS-21 micelle solution. By introducing the surface modified lipid, the stability of the adjuvant is remarkably improved, the adjuvant is small in particle size, uniform in distribution, high in Zeta potential negative value and good in stability in a serum environment, can induce high-level antibody immune response, and is suitable for vaccine development.